Biolytic Lab Performance, Inc. Company Profile
Background
Overview
Biolytic Lab Performance, Inc., established in 1993, specializes in the design, manufacture, and service of advanced DNA and RNA oligonucleotide synthesizers. The company offers comprehensive oligonucleotide synthesis solutions, including high-quality synthesis consumables, pre- and post-synthesis lab accessories, and maintenance services. Their mission is to provide researchers with the tools necessary to create quality oligos tailored to their specific needs.
Mission and Vision
Biolytic's mission is to deliver superior quality, innovative products, and esteemed services that advance research and technology. Their vision is to consistently exceed expectations in safety, quality, delivery, innovation, sustainability, cost, and value, while fostering a culture built on clarity, collaboration, and continual improvement.
Industry Significance
With over 30 years of experience, Biolytic has become a significant player in the biotechnology sector, particularly in oligonucleotide synthesis. Their products and services support a wide range of applications, including diagnostics, therapeutics, and various research fields, thereby contributing to advancements in molecular biology and synthetic biology.
Key Strategic Focus
Core Objectives
Biolytic aims to provide end-to-end oligonucleotide synthesis solutions, ensuring high-quality products and services that meet the evolving needs of biotechnology laboratories worldwide.
Areas of Specialization
The company specializes in the design and manufacture of DNA and RNA oligonucleotide synthesizers, synthesis consumables, and post-synthesis accessories. They also offer maintenance services and technical support to enhance the efficiency and quality of oligo synthesis processes.
Key Technologies Utilized
Biolytic employs advanced technologies in the development of their Dr. Oligo synthesizers, which are capable of synthesizing a wide range of oligonucleotides, including DNA, RNA, LNA, 2'-Modified RNA, and mixed backbone DNA and RNA. These synthesizers are designed for high throughput and reliability, catering to various research and production needs.
Primary Markets Targeted
Biolytic serves a global customer base, including pharmaceutical and biopharmaceutical companies, university laboratories, government institutions, research facilities, startups, and other oligo synthesis companies. Their products are utilized in diagnostics, therapeutics, and various research applications.
Financials and Funding
Funding History
Biolytic has secured funding through grants from the U.S. Department of Health & Human Services (HHS). Notably, they received a grant of $25,509 in September 2019.
Total Funds Raised
The company has raised a total of $25,509 in funding.
Notable Investors
The primary investor is the U.S. Department of Health & Human Services (HHS).
Utilization of Capital
While specific details on the utilization of the capital are not publicly disclosed, it is likely allocated towards research and development, manufacturing enhancements, and expansion of product offerings to meet the growing demands of the biotechnology sector.
Pipeline Development
Biolytic's product development pipeline includes the Dr. Oligo series of synthesizers, such as the Dr. Oligo 12, Dr. Oligo 48, Dr. Oligo 192XLc, and Dr. Oligo 768XLc. These instruments are designed to cater to various throughput requirements, from low to high-volume oligonucleotide synthesis. The company continues to innovate, with recent releases like the Dr. Oligo 12 low throughput DNA/RNA oligo synthesizer launched in 2023.
Technological Platform and Innovation
Proprietary Technologies
Biolytic's proprietary Dr. Oligo synthesizers are engineered for high-volume, high-reliability DNA/RNA synthesis, supporting a wide range of oligonucleotide types and modifications.
Significant Scientific Methods
The company employs advanced synthesis chemistries and automated processes to enhance the efficiency and quality of oligonucleotide production. Their instruments are capable of synthesizing various oligonucleotide types, including modified and mixed backbone sequences, catering to diverse research needs.
Leadership Team
James Demmitt, CEO
James Demmitt serves as the Chief Executive Officer of Biolytic Lab Performance, Inc. Under his leadership, the company has expanded its product offerings and strengthened its position in the biotechnology sector.
Kim Edmonds, Director of Finance and Administration
Kim Edmonds oversees the financial and administrative operations of the company, ensuring efficient management of resources and supporting strategic initiatives.
Torries Emerson, Assistant Controller
Torries Emerson assists in managing the company's financial operations, contributing to the overall financial health and strategic planning of Biolytic.
George Ho, Technical Supervisor
George Ho supervises the technical aspects of product development and manufacturing, ensuring the quality and reliability of Biolytic's synthesizers and related products.
Parker D'Encarnacao, Marketing Lead
Parker D'Encarnacao leads marketing efforts, focusing on promoting Biolytic's products and services to a global audience.
